잠시만 기다려 주세요. 로딩중입니다.

Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery

대한간암학회지 2020년 20권 2호 p.113 ~ 119
임지영, 이민종, 김태훈,
소속 상세정보
임지영 ( Lim Ji-Young ) - Catholic University College of Medicine Eunpyeong St. Mary’s Hospital Department of Health Promotion Center
이민종 ( Lee Min-Jong ) - Ewha Womans University College of Medicine Department of Internal Medicine
김태훈 ( Kim Tae-Hun ) - Ewha Womans University College of Medicine Department of Internal Medicine

Abstract


In the Barcelona Clinic Liver Cancer staging system, intermediate stage hepatocellular carcinoma (HCC) is defined as large multinodular tumors without vascular invasion or extrahepatic spread in an asymptomatic patient with good performance status. Intermediate stage HCC includes various subgroups and it is characterized by extensive heterogeneity. Current guidelines recommend transarterial chemoembolization (TACE) as the standard treatment modality for patients with intermediate stage HCC. Although TACE provides improved survival benefits compared with supportive care for patients with intermediate stage HCC, all of them are not good candidates for TACE. TACE refractoriness is another obstacle to effective treatment of patients with intermediate stage HCC. Given that many studies recently reported improved survival in patients treated with hepatic resection over TACE, we reviewed the survival outcomes of TACE and hepatic resection as a treatment strategy of intermediate stage HCC.

키워드

Surgery; Transarterial chemoembolization; Hepatocellular carcinoma

원문 및 링크아웃 정보

등재저널 정보